PLIANT THERAPEUTICS, INC. 8-K

What Happened Pliant Therapeutics, Inc. (PLRX) filed an 8-K on June 11, 2026 reporting the results of its 2026 Annual Meeting of Stockholders held that day. As of the April 15, 2026 record date there were 61,914,664 shares outstanding. Stockholders elected three Class III director nominees — Bernard Coulie, M.D., Ph.D., MBA; Gayle Crowell; and Steve Krognes, MBA — approved a non-binding advisory vote on executive compensation (say-on-pay), and ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026.

Key Details

• Meeting date and record date: Annual Meeting held June 11, 2026; record date April 15, 2026 (61,914,664 shares outstanding).
• Director votes: Bernard Coulie — For 18,824,540 / Withhold 11,807,308; Gayle Crowell — For 18,186,914 / Withhold 12,444,934; Steve Krognes — For 19,299,728 / Withhold 11,332,120. Broker non-votes for director elections: 11,895,135 shares.
• Say-on-pay (non-binding): For 15,282,788; Against 14,572,455; Abstain 776,605. Broker non-votes: 11,895,135 shares.
• Auditor ratification: Deloitte & Touche LLP ratified — For 41,710,604; Against 747,140; Abstain 69,239. No broker non-votes reported for this proposal.
• Filing signed by Keith Cummings, M.D., MBA, Chief Financial Officer, on June 11, 2026.

Why It Matters These results confirm the company’s board composition for the Class III seats through the 2029 Annual Meeting and show shareholder sentiment on executive pay was closely divided (the say-on-pay passed but with a substantial against vote). Ratification of Deloitte ensures continuity of the company’s external audit for fiscal 2026. Investors should note the sizable number of broker non-votes on governance matters, which can reflect withheld or unvoted shares held in brokerage accounts and may affect the effective voting base on certain proposals.